Study Conduct

Dissuasion in Recruitment Research

Wednesday, January 2, 2008

Of all the techniques considered for affecting the behavior of patients and encouraging their clinical trial participation, nary a single researcher has considered the benefits of dissuasion. It is true on its face the concept seems a bit counterintuitive. After all, typical recruitment approaches involve persuasion, enticement, inducement and have, during less proud times, inched closer toward undue influence. What has not yet been explored is the benefit of dissuasion, or discouraging participants from refusing to participate in voluntary clinical research.

[Read More]

eClinical Technology News

Tuesday, November 20, 2007

Pittsburgh, Pa.-based ePRO company invivodata launched its new version of its EPX management system: EPX ePRO Management System, Version 5.0. The system is web-based and has the capability to manage site performance, patient enrollment and compliance, and data integrity in real-time. The system can also generate user-customized reports and changeable dashboard views. It has an e-mail alert system that signals when items need action taken and boasts the industry’s only electronic data clarification form (EDCF) system to resolve discrepancies in data.

[Read More]

BBK Creates New Global Mobilization Team Division

Tuesday, June 19, 2007

Newton, Mass.-based patient recruitment company BBK Worldwide has created a new company division called the global mobilization team. The company stated that this division will help address the challenges of planning and deploying of resources for large-scale, global trials. BBK stated the division will include in-country staff with expertise in local patient recruitment, a web-based communication structure and real-time access to data essential for making changes in recruitment operations mid-trial.

[Read More]

The Psychology of Clinical Trials: Understanding Physician Motivation and Patient Perception

Wednesday, October 4, 2006

The clinical trials industry has been at the center of public scrutiny following recent news reports of unethical patient recruitment and manipulated trial results. Are these well-publicized stories causing doctors and patients to shy away from experimental treatment? What are the key factors that drive physicians to refer patients into clinical trials and what are patients’ biggest concerns?

To gain a better understanding of the psychology of the clinical trials patient and referring physician, CenterWatch conducted a series of in-depth doctor and patient surveys. The results and related observations, which were presented this June at the Drug Information Association Annual Meeting, are outlined in this CenterWatch Research Brief…

[Read More]

Fighting The Logjam In LatAm Drug Trials

Monday, September 18, 2006

Clinical research in Latin America has grown significantly over the past 10 years but obstacles to continued growth still exist. In our first-ever survey of investigative sites in Latin America, we at Thomson CenterWatch found that bottlenecks at the site level continue to hinder growth of clinical research in the region as researchers strive to improve the system.

[Read More]

Prisoners As Study “Volunteers”

Thursday, August 17, 2006

A recent Institute of Medicine Report has recommended that drug testing be allowed on prisoners, thereby lifting a decades-old ban on this practice. The recommendation is drawing both criticism and support from government and industry.

[Read More]

Is India Ready For Phase I Studies?

Tuesday, August 15, 2006

India has come a long way as a center for clinical drug trials, but is the country ready for Phase I studies? I think the short answer – and others would agree – is “no”. Take, for instance, recent comments by Ashwini Kumar, the Drug Controller General of India (DCGI), who spoke recently at the Drug Information Association’s (DIA) Annual Meeting in Philadelphia. Kumar, head of the Central Drug Standard Control Organization (CDSCO), India’s regulatory agency, said that India needed to create an environment for the best quality assurance before embarking on phase I studies…

[Read More]